Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Mims, Alice S., Prince, Gabrielle T., Altman, Jessica K., Arellano, Martha L., Donnellan, Will, Erba, Harry P., Mannis, Gabriel N., Pollyea, Daniel A., Stein, Anthony S., Uy, Geoffrey L., Watts, Justin M., Fathi, Amir T., Kantarjian, Hagop M., Tallman, Martin S., Choe, Sung, Dai, David, Fan, Bin, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Hickman, Denice, Liu, Hua, Agresta, Samuel V., Wu, Bin, Attar, Eyal C., Stone, Richard M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Plenary Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019193/
https://ncbi.nlm.nih.gov/pubmed/31841594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002140
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars